The newly FDA-approved drug blocks viral replication and RNA transcription via a cap-dependent endonuclease inhibitor.
Rebecca A. Jayakumar, PharmD
Advertisement
Articles by Rebecca A. Jayakumar, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
3
Real-World Use of Talazoparib Plus Enzalutamide and HR Testing Trends in Prostate Cancer
4
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
5